VANCOUVER, British Columbia, Feb. 22, 2018 (GLOBE NEWSWIRE) —
Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that its wholly owned subsidiary Be Trū Wellness (Be Tru) has signed a distribution agreement with Threshold Enterprises.
Threshold Enterprises was established in 1978 and is a wholesale distributor of dietary supplements and health care products to the natural foods industry and health care professionals as well as the parent company of Source Naturals® and Planetary Herbals® brand supplements.
Recognized as one of California’s largest manufacturers and distributors of nutritional supplements and other natural products, Threshold offers more than 300 brands and 15,000 products distributed throughout all 50 states, as well as in international markets.
“This is another major breakthrough for Be Tru,” said CEO of Be Tru, Keith Gordon. “Threshold Enterprises is well known for their many years of experience in the industry and they also have been the recipient of many awards over the years for the quality of their products. Threshold will be another instrumental tool in introducing the Be Tru brand to mainstream North America, as well as international markets.”
Threshold will begin to exhibit Be Tru products at Expo West March 9-11, 2018.
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Trū Wellness, please visit www.betruwellness.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.